OpenAI Broadens Access to GPT-Rosalind for Life Sciences Research

OpenAI has extended GPT-Rosalind's availability beyond initial select partners to include major biotech companies like Amgen and Moderna, facilitating wider adoption in drug discovery. This move signals a strategic push to embed AI more deeply into biological research workflows. Watching upcoming research breakthroughs enabled by GPT-Rosalind will reveal its impact on the field.